SSTR5

SSTR5, or growth inhibitory receptor 5, also known as growth inhibitory receptor subtype 5, SS5-R, Somatostatin receptor type 5, etc. SSTR5 is a G protein-coupled receptors (GPCRs), which is highly expressed mainly in the pituitary gland, and is involved in the regulation of the secretion of a variety of hormones, such as proadrenocorticotropic hormone, prolactin, and growth hormone, etc. The mechanism of action of SSTR5 involves binding to its natural ligand growth inhibitor (SST) or synthetic agonist drugs such as octreotide. The mechanism of action of SSTR5 involves binding to its natural ligand, growth suppressor (SST), or synthetic agonists such as octreotide, which in turn inhibits adenylyl cyclase (AC) activity, and through the inhibitory G-protein (Gi)-mediated modulation of intracellular cAMP concentration, affecting the secretion of hormones and tumor growth, etc.

The biological significance of SSTR5 is mainly reflected in its role as a major endocrine disease regulator. in its role as a potential target for the treatment of a variety of endocrine diseases and tumors.Activation of SSTR5 reduces gallbladder contraction and increases the risk of cholesterol gallstones; therefore, antagonizing SSTR5 may promote gallbladder emptying and reduce gallbladder stone formation . In addition, the expression level of SSTR5 has been associated with the development of certain cancers, for example, it has been found that variations in the SSTR5 gene are associated with the development of cancers such as head and neck cancer, lung cancer, prostate cancer and kidney cancer . Therefore, SSTR5 not only plays an important role in the regulation of hormone secretion and tumor growth, but is also a potential target in drug development and disease treatment.